CD8A and neoplasm: Azelnidipine inhibits the innate checkpoint CD47/CD172a and the adaptive checkpoint TIGIT–CD112 pathways and has anti-cancer effects by increasing the infiltration and function of CD8+ T cell and macrophage tumor cell phagocytosis in vivo and in vitro.